Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Core Viewpoint - Tiziana Life Sciences has announced the withdrawal of its proposed public offering of common shares due to unfavorable market conditions [1]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative immunomodulation therapies, particularly through its lead candidate, intranasal foralumab, which is a fully human anti-CD3 monoclonal antibody [3]. - The company aims to improve the efficacy, safety, and tolerability of immunotherapy by utilizing alternative drug delivery methods, specifically through nasal administration [3]. - Tiziana's technology for alternative routes of immunotherapy has been patented, with several applications pending, indicating potential for broad pipeline applications [3]. Product Information - Foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing promise in stimulating T regulatory cells when administered intranasally [5][6]. - In an open-label intermediate-sized Expanded Access Program, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been treated, with all patients showing either improvement or stability of disease within six months [5]. - Foralumab is also undergoing a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial for patients with non-active secondary progressive multiple sclerosis [5].